Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|June 13, 2014

Catalent and AAPS Announce Winners of Annual Academic Competition

Catalent and AAPS announce the five winners of its annual academic competition.

The Catalent Applied Drug Delivery Institute and the American Association of Pharmaceutical Scientists (AAPS), reported the winners of their “Global Academic Competition for Life Science Leaders of Tomorrow.” Chosen from US and international universities with graduate programs in pharmaceutical science, the five winners were Maren Preis, University of Dusseldorf, “Regulatory Challenges & Available Dosage Forms”; Prachi Shah, St. Johns University, “Double Emulsions: Scope and Attempts”; Nilesh Gupta, Texas Tech University, “Challenges in Developing Inhalation Technology: Right Particle Size and Device Selection”; Tannaz Ramezanli, Rutgers University, “Stem Cells as Novel Carriers for Cancer Therapy”; and Emrah Ilker Ozay, UMass Amherst, “Slipping through the blood brain barrier with cell penetrating peptide mimics.”

Each winner will receive a cash prize of $2,000 and annual membership to the AAPS. The annual competition aims to identify emerging scientific talent, foster drug delivery education, and reward academic excellence. Competition entries consisted of original review articles addressing topics such as drug development, delivery technologies, improving therapeutic profiles and bioavailability, preformulation, and pediatric drugs.


Related to this article

The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.